| Name | Title | Contact Details |
|---|
Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body`s immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company`s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.
BMG Labtech is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.
Roche NimbleGen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.